

KCQA NQF-ENDORSED PERFORMANCE MEASURE TECHNICAL SPECIFICATIONS

MEASURE	DESCRIPTION	NUMERATOR	DENOMINATOR	EXCLUSIONS	DATA SOURCE
<p>NQF 0251: Functional Arteriovenous Fistula (AVF) or AV Graft or Evaluation for Placement</p> <p>Level: Clinician</p>	<p>Percentage of ESRD patients aged 18 years and older receiving HD during the 12-month reporting period and on dialysis >90 days who:</p> <ol style="list-style-type: none"> 1. Have a functional AVF (defined as two needles used or a single-needle device [NOT one needle used in a two-needle device]) (computed and reported separately); or 2. Have a functional AV graft (computed and reported separately); or 3. Have a catheter but have been seen/evaluated by a vascular surgeon, other surgeon qualified in the area of vascular access, or interventional nephrologist trained in the primary placement of vascular access for a functional autogenous AVF or AV graft at least once during the 12-month reporting period (computed and reported separately). 	<p>Number of patients from the denominator who:</p> <ol style="list-style-type: none"> 1. Have a functional AVF (defined as two needles used or a single-needle device [NOT one needle used in a two-needle device]) (computed and reported separately); or 2. Have a functional AV graft (computed and reported separately); or 3. Have a catheter but have been seen/evaluated by a vascular surgeon, other surgeon qualified in the area of vascular access, or interventional nephrologist trained in the primary placement of vascular access for a functional autogenous AVF or AV graft at least once during the 12-month reporting period (computed and reported separately). 	<p>All ESRD patients aged 18 years and older receiving hemodialysis during the 12-month reporting period and on dialysis >90 days.</p> <p>This measure includes both in-center and home hemodialysis patients.</p>	None.	Administrative claims; electronic clinical data; electronic health record; medical records.
<p>NQF 0226: Influenza Immunization in the ESRD Population</p> <p>Level: Facility</p>	<p>All ESRD patients aged 6 months and older receiving HD and/or PD during the time from October 1 (or when the influenza vaccine became available) to March 31 who:</p> <ol style="list-style-type: none"> 1. Receive an influenza vaccination;¹ OR 2. Were assessed and offered an influenza vaccination but decline; OR 3. Were assessed and determined to have a medical contraindication(s) to the influenza vaccination. 	<p>Number of patients from the denominator who:</p> <ol style="list-style-type: none"> 1. Receive an influenza vaccination¹ (documented by the provider or reported receipt from another provider or by the patient) (computed and reported separately); OR 2. Were assessed and offered an influenza vaccination but decline (computed and reported separately); OR 3. Were assessed and determined to have a medical contraindication(s) of anaphylactic hypersensitivity to eggs or other component(s) of the vaccine, history of Guillain-Barre Syndrome within 6 weeks after a previous influenza vaccination, bone marrow transplant with the past 6 months (<6 months prior to encounters between October 1 and March 31) (computed and reported separately). 	<p>All ESRD patients aged 6 months and older receiving hemodialysis and/or peritoneal dialysis during the time from October 1 (or when the influenza vaccine became available) to March 31.</p>	None.	

¹ Only inactivated virus should be used in the ESRD population.